http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Poseida Therapeutics (PSTX) Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen
-
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen
-
Poseida Therapeutics (PSTX) Announces FDA Clearance of IND Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors
-
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors
-
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting
-
Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021
-
Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting
-
Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences
-
Poseida Therapeutics (PSTX) announces Johanna Mylet will serve as Chief Financial Officer
-
Poseida Therapeutics Announces Leadership Appointments
-
Poseida Therapeutics (PSTX) Enters Research Collaboration with Takeda (TAK) for Novel Non-Viral In Vivo Gene Therapies
-
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies
-
Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting
-
Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences
-
Poseida Therapeutics (PSTX) Presents Positive Preliminary Results from Phase 1 Trial of P-PSMA-101
-
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit
-
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
-
Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021
-
Poseida Therapeutics (PSTX) Appoints Cynthia Collins to its Board
-
Poseida Therapeutics Appoints Cynthia Collins to Board of Directors
-
Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders
-
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021
-
Poseida Therapeutics (PSTX) Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs
-
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting
-
Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board
-
Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference
-
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting
-
Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences
-
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
-
Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020
-
Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day
-
Poseida Therapeutics to Host Virtual R&D Day on February 24, 2021
-
Poseida Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
-
Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event
-
Poseida Therapeutics Added to NASDAQ Biotechnology Index
-
Poseida Therapeutics (PSTX) Adds Luke Corning to Board
-
Poseida Therapeutics Appoints Luke Corning to Board of Directors
